Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients
NCT05839288 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 161
Last updated 2023-05-03
Summary
To evaluate the patterns and treatment outcomes of pyrotinib plus trastuzumab and chemotherapy in the real world.
Conditions
Sponsors & Collaborators
-
Fudan University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-11-01
- Primary Completion
- 2023-03-01
- Completion
- 2023-04-01
Countries
- China
Study Locations
More Related Trials
-
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
NCT06770296 ·Status: RECRUITING ·Phase: PHASE1
-
Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib
NCT05020964 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer
NCT03923179 ·Status: UNKNOWN ·Phase: PHASE2
-
Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )
NCT04033172 ·Status: UNKNOWN ·Phase: PHASE2
-
A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2
NCT03908749 ·Status: UNKNOWN
-
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer
NCT04158505 ·Status: UNKNOWN
-
Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
NCT03412383 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer
NCT01937689 ·Status: COMPLETED ·Phase: PHASE1
-
Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study
NCT03919253 ·Status: UNKNOWN ·Phase: PHASE2
-
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
NCT05910398 ·Status: RECRUITING ·Phase: PHASE3
-
Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer
NCT05255523 ·Status: UNKNOWN ·Phase: PHASE2
-
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
NCT06035016 ·Status: RECRUITING
-
Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab
NCT04255056 ·Status: UNKNOWN ·Phase: PHASE2
-
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
NCT06254690 ·Status: RECRUITING ·Phase: PHASE2
-
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
NCT04254263 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer
NCT04293276 ·Status: UNKNOWN ·Phase: PHASE2
-
Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer
NCT04917900 ·Status: UNKNOWN ·Phase: PHASE2
-
Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer
NCT04407988 ·Status: UNKNOWN ·Phase: PHASE2
-
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
NCT04152057 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
NCT04001634 ·Status: COMPLETED
-
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
NCT05561686 ·Status: UNKNOWN
-
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
NCT03980054 ·Status: UNKNOWN ·Phase: PHASE3
-
The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive
NCT06495541 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer
NCT03993964 ·Status: UNKNOWN ·Phase: PHASE2
-
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer
NCT04659499 ·Status: UNKNOWN ·Phase: PHASE2